Rimas V. Lukas, MD

Articles

Dr. Rimas Lukas on Controlled Interleukin-12 Combined With a PD-1 Inhibitor in Recurrent Glioblastoma

June 12th 2019

Cancer Network spoke with Rimas V. Lukas, MD, of Northwestern University Feinberg School of Medicine, about the combination of controlled interleukin-12 with a PD-1 inhibitor in recurrent glioblastoma.

Newly Diagnosed Glioblastoma: A Review on Clinical Management

Rimas V. Lukas, MD;Derek A. Wainwright, PhD;Erik Ladomersky, PhD;Sean Sachdev, MD;Adam M. Sonabend, MD;Roger Stupp, MD

March 13th 2019

This review focuses on clinical developments and management of newly diagnosed glioblastoma, and includes a discussion about the incorporation of molecular features into the classification of this disease.

Primary Central Nervous System Lymphoma-PART 2: Modern Therapeutic Management and Future Directions

Rimas V. Lukas, MD;Vinai Gondi, MD;Roger Stupp, MD;Jeffrey J. Raizer, MD

February 15th 2018

In Part 2 of this review article, we discuss the management of primary CNS lymphoma, focusing in particular on systemic therapies and radiation, as well as provide clinicians with a comprehensive overview by covering the key investigations that have brought us to our current state of knowledge, and studies that may guide future interventions.

Primary Central Nervous System Lymphoma-PART 1: Epidemiology, Diagnosis, Staging, and Prognosis

Rimas V. Lukas, MD;Roger Stupp, MD;Vinai Gondi, MD;Jeffrey J. Raizer, MD

January 15th 2018

Here, in Part 1, we will provide an overview of the epidemiology of primary CNS lymphoma, followed by a discussion of the diagnostic and staging evaluation. We will also review the current prognostication systems for primary CNS lymphoma.

Management of Leptomeningeal Disease From Solid Tumors

Rimas V. Lukas, MD;Robin Buerki, MD, MPH;Maciej M. Mrugala, MD, PhD, MPH

August 16th 2016

Metastasis of solid tumors to the cerebrospinal fluid is a serious complication of cancer. Although it can occur with any type of cancer, tumors with a high propensity for CNS involvement (brain metastases) are the most likely to spread to the cerebrospinal fluid.